Ultrasound Mediated Delivery of Drugs
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 15/024,265, filed Mar 24, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,343,396 | Ultrasound Mediated Delivery of Drugs In force · High confidence | Exact Therapeutics As | In force | High confidence | ||
| US 12,377,146 | Method of Using High-Frequency Sound Waves In force · Low confidence | Exact Therapeutics As | In force | Low confidence | ||
| US 12,478,676 | Method of Imaging In force · High confidence | Exact Therapeutics As | In force | High confidence | ||
| Application 15/024,265 | Ultrasound Mediated Delivery of Drugs Abandoned Abandoned Nov 13, 2023 | Exact Therapeutics As | Abandoned | Abandoned Nov 13, 2023 | ||
| Application 18/187,244 | Method of Manufacturing an Embolizing Agent Precursor Abandoned Abandoned Dec 14, 2024 | Exact Therapeutics As | Abandoned | Abandoned Dec 14, 2024 | ||
| Application 18/187,413 | Embolizing Agent Precursor Pharmaceutical Composition Abandoned Abandoned May 16, 2024 | Exact Therapeutics As | Abandoned | Abandoned May 16, 2024 | ||
| Application 19/344,192 | Ultrasound Mediated Delivery of Drugs Pending Not granted | Exact Therapeutics As | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Exact Therapeutics As.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.